Category Archives: Corporate Responsibility
By Guest Blogger | Published: August 29, 2012
By Susan Crowley Public policy activities should be a distinct, mission critical function for Big Pharma — our business depends increasingly on government as a key customer. However, as companies confront the necessity to plump up the bottom line as patents expire, staffing of non-line functions has taken a big hit, with policy advocacy work emerging [...]
By Ben Comer | Published: August 21, 2012
Over the counter drug advertising is less regulated than prescription drug marketing, and selling directly to consumers comes with the benefit of bypassing an expert middleman: your doctor. But companies should still promote with caution.
By Ben Comer | Published: August 7, 2012
Forest Labs has had a tough time with regulators over the last two years. The company’s sales reps can’t seem to stop breaking the law. The latest offense, which generated an Untitled Letter from the Office of Prescription Drug Promotion (OPDP), was brought to light through OPDP’s Bad Ad program, which encourages physicians to report on [...]
By Ben Comer | Published: July 20, 2012
At CBI’s 7th Annual Rare Disease and Orphan Drug Leadership Congress, speakers and attendees identified areas where pharma can improve the way it approaches rare disease and treatment.
By Ben Comer | Published: July 6, 2012
Big pharma talks a lot about the changing business model and placing a new emphasis on patients, but the fact remains that quantity of medicines sold, not quality of care provided, is how to get paid (and how to keep investors happy). Despite its egalitarian trappings, the healthcare “ecosystem” is still dominated by the [...]